Standard BioTools Inc. Proceeds from Common Stock Issued
Standard BioTools Inc. (LAB) reported Proceeds from Common Stock Issued of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2022-03-08
- Standard BioTools Inc. proceeds from issuance of common stock for the quarter ending 2021-12-31 was $0.00.
- Standard BioTools Inc. proceeds from issuance of common stock for the quarter ending 2020-12-31 was $0.00.
- Standard BioTools Inc. proceeds from issuance of common stock for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- Standard BioTools Inc. proceeds from issuance of common stock for the quarter ending 2018-12-31 was $58.91M.
- Standard BioTools Inc. proceeds from issuance of common stock for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Standard BioTools Inc. proceeds from issuance of common stock for fiscal 2020 was $20.23M.
- Standard BioTools Inc. proceeds from issuance of common stock for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- Standard BioTools Inc. proceeds from issuance of common stock for fiscal 2018 was $59.47M, a 106.54% increase from fiscal 2017.
| Period end | Proceeds from Issuance of Common Stock 0 month | Proceeds from Issuance of Common Stock 1 month | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month | Proceeds from Issuance of Common Stock 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $0.00 10-K · filed 2022-03-08 | |||||
| 2021-09-30 | $0.00 10-Q · filed 2021-11-09 | ||||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $20.23M 10-K · filed 2022-03-08 | |||||
| 2020-09-30 | $20.23M 10-Q · filed 2021-11-09 | ||||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $0.00 10-K · filed 2022-03-08 | |||||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-09 | ||||||
| 2018-12-31 | $58.91M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $58.91M derived: sum of 2 quarters · filed 2021-02-25 | $59.47M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $562.00K 10-Q · filed 2018-11-06 | |||||
| 2018-06-30 | $562.00K 10-Q · filed 2018-08-08 | ||||||
| 2017-12-31 | -$50.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $28.79M derived: sum of 2 quarters · filed 2020-02-27 | $28.79M 10-K · filed 2020-02-27 | $29.02M 10-K · filed 2018-03-08 | |||
| 2017-09-30 | $28.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $28.84M 10-Q · filed 2018-11-06 | |||||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-08 | ||||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $0.00 10-K · filed 2019-03-18 | |||||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-07 | ||||||
| 2015-12-31 | $0.00 10-K · filed 2018-03-08 | ||||||
| 2013-09-30 | $0.00 10-Q · filed 2013-11-07 | ||||||
| 2012-09-30 | $56.14M 10-Q · filed 2013-11-07 | ||||||
| 2012-08-21 | $56.10M 10-Q · filed 2012-11-09 | ||||||
| 2011-02-28 | $77.00M 10-Q · filed 2012-08-14 | ||||||
| 2011-02-15 | $77.00M 10-K · filed 2014-03-12 | ||||||
| 2011-02-09 | $77.00M 10-Q · filed 2012-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |